NEUROBO PHARMACEUTICALS INC (NRBO) Stock Earnings & Estimates
NASDAQ:NRBO - US64132R4048 - Common Stock
2.36 USD
+0.01 (+0.43%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | |||||||||||
| EBITDA YoY % growth | N/A | N/A | N/A | N/A | -22.81M | -8M 64.93% | -12.33M -54.12% | -15.25M -23.68% | -11.4M 25.25% | -15.88M -39.30% | N/A | N/A | N/A | |
| EBIT YoY % growth | -270K | -7.16M -2,551.85% | -14.7M -105.31% | -33.12M -125.31% | -22.81M 31.13% | -8.02M 64.84% | -12.38M -54.36% | -15.3M -23.59% | -11.42M 25.36% | -15.886M -39.11% | N/A -99.62% | N/A 15.35% | N/A -12.90% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -2,242.50 -47.31% | -1,305.00 41.81% | N/A 79.37% | -55.20 79.50% | N/A | N/A | -3.93 95.84% | N/A -4.04% | N/A 61.06% | N/A 9.92% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.67 70.77% | -0.60 54.29% | -0.36 80.70% | -0.37 33.24% | -0.41 37.93% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -8.031M -41.72% | -8.088M -17.54% | -6.777M 32.79% | -7.049M -12.62% | -7.796M 2.93% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.55 23.61% | -0.74 | 0.19 | 26.13% |
| Q2 2024 Q2Q % growth | -1.85 -1,056.25% | -1.15 | -0.70 | -61.46% |
| Q1 2024 Q2Q % growth | -1.32 -72.20% | -3.70 | 2.38 | 64.34% |
| Q4 2023 Q2Q % growth | -2.28 84.34% | -0.80 | -1.48 | -184.75% |
| Q3 2023 Q2Q % growth | -0.72 -315.22% | -0.87 | 0.15 | 17.54% |
| Q2 2023 Q2Q % growth | -0.16 7.73% | -1.03 | 0.87 | 84.44% |
| Q1 2023 Q2Q % growth | -0.77 -369.71% | -5.14 | 4.37 | 85.09% |
| Q4 2022 Q2Q % growth | -14.56 -9,416.34% | -9.79 | -4.77 | -48.69% |
| Q3 2022 Q2Q % growth | 96.39% | -0.17 | % | |
| Q2 2022 Q2Q % growth | 96.79% | -0.17 | % | |
| Q1 2022 Q2Q % growth | 96.37% | -0.16 | % | |
| Q4 2021 Q2Q % growth | 99.58% | -0.15 | % | |
| Q3 2021 Q2Q % growth | -4.80 15.79% | -5.51 | 0.71 | 12.85% |
| Q2 2021 Q2Q % growth | -5.40 -20.00% | -4.59 | -0.81 | -17.65% |
| Q1 2021 Q2Q % growth | -4.50 50.00% | -4.90 | 0.40 | 8.09% |
| Q4 2020 Q2Q % growth | -36.00 64.39% | -5.81 | -30.19 | -519.20% |
| Q3 2020 Q2Q % growth | -5.70 | -5.20 | -0.50 | -9.57% |
| Q2 2020 Q2Q % growth | -4.50 97.00% | -5.81 | 1.31 | 22.60% |
| Q1 2020 Q2Q % growth | -9.00 | -3.06 | -5.94 | -194.12% |
| Q4 2019 Q2Q % growth | -101.10 | -6.12 | -94.98 | -1,551.96% |
| Q2 2019 Q2Q % growth | -150.00 | -118.58 | -31.42 | -26.50% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 27% | 26.04% | 8.67% | 8.67% |
| Revenue | N/A | N/A | N/A | N/A |